ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations
Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate Read More
ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes
Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate Read More
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Research Triangle Park, NC, USA, Cambridge, UK, Irvine, Calif., and Amsterdam – 28 April 2021 Read More
Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial Read More
